Medicare Covers GLP-1 Weight-Loss Drugs Starting July 1: What to Know
For the first time, qualifying Medicare beneficiaries can access GLP-1 weight-loss drugs at $50/month beginning July 1.
A significant shift in federal health coverage takes effect this summer: Medicare will for the first time extend coverage of GLP-1 medications — the class of drugs that includes blockbusters like Ozempic and Wegovy — specifically for weight loss. Beginning July 1, eligible beneficiaries can access these treatments for roughly $50 per month, a dramatic reduction from the out-of-pocket costs that have placed these drugs beyond reach for millions of older Americans.
The policy change represents a meaningful expansion of what Medicare will pay for, a program that has historically excluded obesity treatment as a standalone condition. For the estimated tens of millions of Americans over 65 who struggle with obesity-related health risks, the timing matters: weight has been linked to conditions ranging from Type 2 diabetes to cardiovascular disease, many of which already burden the Medicare system with enormous costs.
Read more Trump's Iran Deal Draws Skepticism From Key GOP Voters →
But access at an affordable price point does not mean the decision is straightforward. Clinicians and patients alike are being urged to weigh meaningful trade-offs. GLP-1 drugs are associated with a range of side effects — nausea, gastrointestinal distress, and in some cases more serious complications — and there is growing clinical attention to the issue of muscle loss, which carries particular risks for older adults already vulnerable to sarcopenia and falls. For seniors, preserving muscle mass is not a cosmetic concern but a functional one tied directly to independence and long-term health outcomes.
The analytical question hanging over this expansion is whether the $50 monthly cost threshold will make GLP-1s genuinely accessible to the Medicare population or whether additional barriers — prior authorization requirements, qualifying criteria, and physician gatekeeping — will limit real-world uptake. Policymakers and patient advocates will be watching closely to see how quickly and equitably coverage translates into prescriptions filled.
Continue reading at MarketWatch.com
